35 completed, 8 terminated, 7 active not recruiting, 5 recruiting. 58 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 58 | Completed 35, Terminated 8, Active not recruiting 7, Recruiting 5, Unknown 2, Not yet recruiting 1 |
| Phase 2 | 5 | Completed 3, Not yet recruiting 1, Unknown 1 |
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Placebo, Elritercept - Myelofibrosis, Anemia | Phase 3 | Recruiting | Takeda | 324 | 2026-09-10 | 2026-10-01 |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Pelabresib, Ruxolitinib, Placebo - Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 460 | 2026-05-27 | 2026-10-26 |
| Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 196 | 2026-05-01 | 2026-04-20 |
| P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk Ropeginterferon alfa-2b, Placebo - Primary Myelofibrosis, Myeloproliferative Neoplasm | Phase 3 | Active not recruiting | PharmaEssentia | 160 | 2025-07-18 | 2026-08-13 |
| Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib Navtemadlin, Navtemadlin placebo, Ruxolitinib - Myelofibrosis, Post-PV MF | Phase 3 | Recruiting | Kartos Therapeutics, Inc. | 600 | 2024-06-03 | 2025-09-25 |
| A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2024-05-23 | 2026-04-02 |
| AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms Direct Oral Anticoagulants, Low-dose aspirin - Polycythemia Vera, Essential Thrombocythemia | Phase 3 | Recruiting | University Hospital, Brest | 1308 | 2022-07-13 | 2026-03-20 |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 177 | 2021-05-26 | 2025-10-02 |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 252 | 2021-05-24 | 2025-10-21 |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Imetelstat, Best Available Therapy (BAT) - Myelofibrosis | Phase 3 | Active not recruiting | Geron Corporation | 327 | 2021-04-12 | 2026-07-08 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) Pelabresib, Ruxolitinib, Placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 430 | 2021-04-09 | 2026-07-17 |
| Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Selinexor, Placebo, Ruxolitinib - Myelofibrosis | Phase 3 | Active not recruiting | Karyopharm Therapeutics Inc | 353 | 2021-03-11 | 2026-10-01 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions ACE-536, Placebo - Myeloproliferative Disorders, Myelofibrosis | Phase 3 | Active not recruiting | Celgene | 313 | 2021-02-25 | 2026-07-16 |
| Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets - Myelofibrosis | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 105 | 2021-02-05 | 2023-11-13 |
| Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis Placebo for Navitoclax, Ruxolitinib, Navitoclax - Myelofibrosis (MF) | Phase 3 | Completed | AbbVie | 252 | 2020-09-29 | 2026-03-23 |
| Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis Navitoclax, Ruxolitinib, Best Available Therapy (BAT) - Myelofibrosis (MF) | Phase 3 | Active not recruiting | AbbVie | 330 | 2020-08-31 | 2026-01-09 |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) Momelotinib, Placebo to match danazol, Danazol - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Completed | Sierra Oncology LLC - a GSK company | 195 | 2020-02-07 | 2023-11-01 |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB, Best Available Therapy (BAT) - Primary Myelofibrosis, Post-Polycythemia Vera | Phase 3 | Completed | Celgene | 202 | 2019-09-09 | 2025-08-28 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Terminated | Celgene | 38 | 2019-03-27 | 2024-12-12 |
| KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment KRT-232, Best Available Therapy (BAT) - Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF) | Phase 2 / Phase 3 | Unknown | Kartos Therapeutics, Inc. | 385 | 2019-01-15 | 2023-04-28 |
Showing 20 of 58. Sign in to see all of them.
Myeloproliferative Disorders (30) · Leukemia, Myeloid, Accelerated Phase (23) · Leukemia, Myeloid, Chronic-Phase (23) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (23) · Blast Crisis (22) · Burkitt Lymphoma (22) · Leukemia, Lymphocytic, Chronic, B-Cell (22) · Lymphoma, Non-Hodgkin (22) · Lymphoma, B-Cell, Marginal Zone (21) · Lymphoma, Follicular (21) · Lymphoma, Large B-Cell, Diffuse (21) · Lymphoma, Large-Cell, Immunoblastic (21) · Lymphoma, Mantle-Cell (21) · Leukemia, Myeloid, Acute (20)
Hemic and Lymphatic Diseases (58) · Bone Marrow Diseases (54) · Hematologic Diseases (54) · Pathological Conditions, Signs and Symptoms (29) · Myeloproliferative Disorders (28) · Pathologic Processes (26) · Chronic Disease (25) · Disease Attributes (25) · Hemorrhagic Disorders (25) · Leukemia, Myeloid (25) · Neoplasms by Histologic Type (25) · Neoplasms by Site (25) · Immune System Diseases (24) · Immunoproliferative Disorders (24) · Leukemia, Lymphoid (24)
ruxolitinib (15) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (3) · Cyclophosphamide (3) · Early Intervention, Educational (3) · Hydroxyurea (3) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (3) · Danazol (2) · Mycophenolic Acid (2) · Peripheral Blood Stem Cell Transplantation (2) · Psychiatric Rehabilitation (2) · Whole-Body Irradiation (2) · fedratinib (2) · liposomal amphotericin B (2) · luspatercept (2) · navitoclax (2)
Novartis Pharmaceuticals (7) · Celgene (4) · Fred Hutchinson Cancer Center (3) · Incyte Corporation (3) · Sierra Oncology LLC - a GSK company (3) · AbbVie (2) · Alliance for Clinical Trials in Oncology (2) · CTI BioPharma (2) · Kartos Therapeutics, Inc. (2) · Memorial Sloan Kettering Cancer Center (2) · Vanderbilt-Ingram Cancer Center (2) · Case Comprehensive Cancer Center (1) · Dartmouth-Hitchcock Medical Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1)
United States (45) · Italy (25) · France (24) · Germany (24) · United Kingdom (24) · Canada (23) · Spain (23) · Belgium (22) · Australia (21) · Hungary (18) · Poland (18) · Austria (17) · Israel (17) · South Korea (17) · Czechia (16)
Simran Singh (2) · Albert Assad, M.D (1) · Albert Assad, M.D. (1) · Alessandro Rambaldi, MD (1) · Barry J.A. Laird, MD (1) · Beth Ziemba (1) · David J. Straus, MD (1) · Debra Barton, RN, PhD, AOCN, FAAN (1) · Eduardo Bruera, MD (1) · Garrett Nichols, MD, MSC (1) · Gautam Borthakur (1)
PMID 37042865, PMID 39516087, PMID 40535755, PMID 41958363, PMID 42316774, PMID 23911705, PMID 26069290, PMID 28962635, PMID 33275766, PMID 42452788, PMID 15459300, PMID 17397698, PMID 19270260, PMID 20424252, PMID 22081489, PMID 22157574, PMID 22375970, PMID 22375971, PMID 22480131, PMID 23423753, PMID 24038026, PMID 24056820, PMID 24174625, PMID 25616577, PMID 25682576, PMID 26228487, PMID 26380150, PMID 26700120, PMID 26700123, PMID 27020837, PMID 27247324, PMID 27773929, PMID 28096091, PMID 28228106, PMID 28606598, PMID 28935847, PMID 29275119, PMID 29895954, PMID 31235325, PMID 32017044, PMID 32628342, PMID 33210570, PMID 33232476, PMID 33420905, PMID 34002031, PMID 34551507, PMID 35510486, PMID 35950489, PMID 36282798, PMID 36709073
2023 (5), 2018 (2), P30CA068485 (2), 2009 (1), 2014 (1), 2025 (1), P30CA069533 (1), R01CA112631 (1), R01CA119196 (1), R01CA127655 (1)